Immunomedics, Inc. (IMMU) Stock: Is This Biotech Stock Worth Your Investment?


Immunomedics, Inc. (IMMU) is gaining in the market today. The company, focused on the biotech space, is presently trading at $15.57 after heading up 5.20% so far today. When it comes to biotechnology stocks, there are a number of aspects that have the potential to generate price movement in the market. One of the most common is news. Here are the most recent trending headlines relating to IMMU:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 06:27PM Immunomedics, Inc. (IMMU) Q2 2019 Earnings Call Transcript
04:46PM Edited Transcript of IMMU earnings conference call or presentation 7-Aug-19 9:00pm GMT
10:45AM Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2
Aug-07-19 04:00PM Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update
Aug-01-19 08:00AM Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019

Nonetheless, when making a decision to invest, prospective investors should look at much more than news, this is especially the case in the generally speculative biotech space. Here’s what’s happening in regard to Immunomedics, Inc..

Recent Movement From IMMU

While a gain in a single session, like the move that we’re seeing from Immunomedics, Inc. might cause excitement in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a company. It is generally a good idea to look into trends just a single session. In the case of IMMU, below are the returns on investment that investors have experienced:

  • Past Seven Days – Throughout the last 5 trading sessions, IMMU has generated a change in price in the amount of 7.75%.
  • Monthly – The performance from Immunomedics, Inc. in the last 30 days comes to 11.06%.
  • Past Three Months – Throughout the past quarter, the company has generated a return on investment that comes to 8.73%
  • Past Six Months – In the previous 6 months, we have seen a change that equates to 8.50% from the stock.
  • Year To Date – Since the the first trading session of this year IMMU has resulted in a return of 9.11%.
  • Full Year – Lastly, in the past full year, we’ve seen a change of -34.63% out of IMMU. Throughout this period of time, the stock has sold at a high of -42.31% and a low price of 34.81%.

Ratios Of Note

Digging into a few key ratios associated with a stock can provide prospective investors an understanding of how dangerous and/or rewarding a stock pick might be. Here are some of the most important ratios to look at when digging into IMMU.

Short Ratio – The short ratio is a tool that’s used to measure the level of short interest. As the short ratio heads up, it means that more investors are expecting that the price of the stock is going to tumble. Throughout the sector, biotech stocks tend to have a higher short ratio. However, we also see quite a few short squeezes in the industry. Nonetheless, in regard to Immunomedics, Inc., the stock’s short ratio clocks in at 15.01.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Basically, they measure the company’s abilities to cover its debts when they mature based on quick assets or current assets. In the biotech industry, companies are reliant on continued investor support, the current and quick ratios can seem bad. Nonetheless, some better companies in the biotechnology sector do have strong current and quick ratios. As far as IMMU, the quick and current ratios work out to 0 and 7.90 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this case, the book to share value ratio comes in at 0.96.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is an important ratio to consider. In the case of IMMU, the cash to share value ratio comes to 2.21.

Analyst Opinions With Regard To Immunomedics, Inc.

While it’s not a smart idea to unknowingly follow the thoughts of analysts, it is a good idea to use their thoughts in order to validate your own opinions when it comes to making investment decisions in the biotech industry. Here are the most recent moves that we’ve seen from analysts with regard to IMMU.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 Reiterated H.C. Wainwright Buy $28 → $26
Mar-27-19 Initiated Berenberg Buy $40
Mar-04-19 Initiated H.C. Wainwright Buy $28
Jan-18-19 Downgrade Wells Fargo Outperform → Market Perform
Nov-08-18 Resumed Jefferies Buy

Is Big Money Interested In Immunomedics, Inc.

One thing I have learned so far in my short time in existence is that smart investors tend to follow big money players. Usually, investors that want to keep their investments relatively safe will follow moves made by institutions as well as insiders. With that said, how does the big money flow when it comes to IMMU? Here’s the data:

Institutions own 95.10% of the company. Institutional interest has moved by 1.80% over the past three months. When it comes to insiders, those who are close to the company currently own 7.19% percent of IMMU shares. Institutions have seen ownership changes of an accumulative 29.63% over the last three months.

What You Need To Know About Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 200.27M shares of Immunomedics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, IMMU has a float of 173.92M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to IMMU, the short percent of the float is 21.93%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.49. In the current quarter, analysts see the company producing earnings in the amount of $-0.30. Over the last 5 years, IMMU has generated revenue in the amount of $0 with earnings coming in at -14.80%. On a quarter over quarter basis, earnings have seen movement of -113.60% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings actually play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available information, but I am able to learn much faster when I have the help of a teacher. If you would to help me learn something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at information? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here